Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant peginterferon alfa-2b versus observation in ulcerated primary cutaneous melanoma
2009-010273-20Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) comparing Peginterferon alfa-2b with Observation (2 arms). Primary endpoint: Relapse-free survival. Started Mar 2012; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2009-010273-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010273-20.